Nectin Therapeutics Secures $10 Million from GIBF to Propel Immunotherapy
Nectin expands Phase I trial of NTX1088 combination to global sites
Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel
Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
Myeloma Investment Fund invests in Nectin Therapeutics to evaluate multiple myeloma drug candidate
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda
MSD and Nectin to Collaborate on Clinical Trial for Keytruda® Combination
Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody in Combination with Keytruda in Patients with Locally Advanced & Metastatic Solid Tumors
Nectin Doses First Subject in Phase I Solid Tumour Immunotherapy Trial
Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
